Lung Cancer Drug Tabrecta Approved By The FDA — New Hope For People With a Specific Biomarker

Published May 7, 2020

Lung Cancer Drug Tabrecta Approved By The FDA — New Hope For People With a Specific Biomarker

The FDA's approval of Tabrecta marks a historic step in treatment for patients battling aggressive lung cancer. Researchers say this is just the beginning.

NOW
PLAYING
It’s World Lung Cancer Day: How Have Treatment Options Changed for Lung Cancer Patients?
NOW
PLAYING
FDA: Risks to Myeloma Patients Taking Pepaxto After Deaths in Trial
NOW
PLAYING
FDA Approves Combination of Keytruda & Lenvima For Treatment Of Advanced Uterine Cancer: What Women Need To Know
NOW
PLAYING
Lung Cancer Patients Who Quit Smoking Live Longer
NOW
PLAYING
First Melanoma Patient Gets mRNA Cancer Vaccine From Medical Company That Cracked COVID; How Does mRNA Work?
NOW
PLAYING
87% of Eligible Patients Skip Lung Cancer Screening, Analysis Finds

SurvivorNetTV.
Hope. Science.
Inspiration.

WATCH NOW
×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.